Yayın: Pharmacokinetics and bioavailability of marbofloxacin in lambs following administration of intravenous, intramuscular and subcutaneous
| dc.contributor.author | Altan, Feray | |
| dc.contributor.author | Corum, Orhan | |
| dc.contributor.author | Corum, Duygu Durna | |
| dc.contributor.author | Atik, Orkun | |
| dc.contributor.author | Uney, Kamil | |
| dc.date.accessioned | 2026-01-05T22:47:56Z | |
| dc.date.issued | 2018-02-01 | |
| dc.description.abstract | Abstract In this study, the pharmacokinetic disposition and bioavailability of marbofloxacin (MB) were determined in lambs after single intravenous (IV), intramuscular (IM), and subcutaneous (SC) administrations at a dose of 3 mg/kg. The plasma concentration of MB was measured using high-performance liquid chromatography-UV, and the pharmacokinetic parameters were analyzed using a non-compartmental analysis. Following IV, IM, and SC administrations, the mean terminal half-life (t1/2ʎz) was 11.48, 12.64, and 24.86 h, respectively, and the mean residence time (MRT) was 7.27, 7.81, and 10.11 h, respectively. The bioavailability (F) was 96.01 and 126.39%, after IM and SC administration, respectively. This study showed that SC administration of MB at a dose of 3 mg/kg exhibited flip-flop pharmacokinetics in lambs. These results suggested that MB could be useful in the treatment of severe systemic infections, such as those with M. haemolytica (MIC = 0.035 μg/mL), in lambs since high AUC0-24/MIC and Cmax/MIC ratios were achieved after IV and IM administration at 3 mg/kg. However, MB administration (3 mg/kg) via the IV, IM, and SC routes might not be effective in the treatment of respiratory infections caused by organisms with MIC90 value in lambs. | |
| dc.description.uri | https://doi.org/10.1016/j.smallrumres.2017.12.004 | |
| dc.description.uri | https://dx.doi.org/10.1016/j.smallrumres.2017.12.004 | |
| dc.description.uri | https://avesis.deu.edu.tr/publication/details/d6688b1d-5f2f-41b3-8ded-8507a7c6f5c8/oai | |
| dc.description.uri | https://hdl.handle.net/11468/16047 | |
| dc.description.uri | https://hdl.handle.net/20.500.12395/36837 | |
| dc.identifier.doi | 10.1016/j.smallrumres.2017.12.004 | |
| dc.identifier.endpage | 10 | |
| dc.identifier.issn | 0921-4488 | |
| dc.identifier.openaire | doi_dedup___::124ca2e32a6d64f83e3b22e90ba91973 | |
| dc.identifier.orcid | 0000-0002-9017-763x | |
| dc.identifier.orcid | 0000-0003-3168-2510 | |
| dc.identifier.orcid | 0000-0003-2411-7492 | |
| dc.identifier.orcid | 0000-0002-8674-4873 | |
| dc.identifier.scopus | 2-s2.0-85037992216 | |
| dc.identifier.startpage | 5 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/43366 | |
| dc.identifier.volume | 159 | |
| dc.identifier.wos | 000425074600002 | |
| dc.language.iso | eng | |
| dc.publisher | Elsevier BV | |
| dc.relation.ispartof | Small Ruminant Research | |
| dc.rights | CLOSED | |
| dc.subject | Lamb | |
| dc.subject | Pharmacokinetics | |
| dc.subject | Marbofloxacin | |
| dc.subject | Fluoroquinolones | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Pharmacokinetics and bioavailability of marbofloxacin in lambs following administration of intravenous, intramuscular and subcutaneous | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.import.source | OpenAire | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus |
